On 30th June, 2017, PATH and Xiamen Innovax Biotech Co., Ltd (Innovax) finalized the Collaboration and Global Access agreement under which PATH will provide technical assistance to support Innovax in obtaining World Health Organization prequalification for its HPV2 vaccine and to fulfill its commitments for supplying the vaccine in developing countries. Innovax is committed to increasing the availability of high-quality vaccines to combat infectious disease globally, and PATH works with manufacturers to provide safe, effective, and affordable new vaccines.
PATH is the leader in global health innovation. An international nonprofit, PATH saves lives and improves health, especially among women and children. PATH accelerates innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovations—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, PATH takes innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. With these key partners, PATH delivers measurable results that disrupt the cycle of poor health.
Xiamen Innovax Biotech Co., Ltd. (INNOVAX), with its premises located in a coastal city in East China, was established in 2005. Being a wholly owned subsidiary of Beijing Wantai Biological Pharmaceutical Co., LTD. under the Yang Sheng Tang Group, INNOVAX is dedicated to developing and manufacturing innovative vaccines, with the mission of providing high-quality and affordable innovative vaccines for people in need worldwide.